AIM Vaccine Future Growth
Future criteria checks 3/6
AIM Vaccine is forecast to grow revenue at 56.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 35.4% |
Revenue growth rate | 56.4% |
Future return on equity | 23.1% |
Analyst coverage | Low |
Last updated | 21 Feb 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 4,673 | N/A | N/A | N/A | 1 |
12/31/2024 | 3,407 | N/A | N/A | N/A | 1 |
12/31/2023 | 1,187 | -1,301 | -405 | -165 | N/A |
9/30/2023 | 1,200 | -913 | -593 | -224 | N/A |
6/30/2023 | 1,213 | -525 | -781 | -283 | N/A |
3/31/2023 | 1,239 | -422 | -874 | -197 | N/A |
12/31/2022 | 1,264 | -320 | -967 | -110 | N/A |
12/31/2021 | 1,570 | -693 | -1,032 | 93 | N/A |
12/31/2020 | 1,638 | 379 | -416 | 250 | N/A |
12/31/2019 | 952 | 117 | 12 | 327 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6660's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if 6660's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 6660's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6660's revenue (56.4% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 6660's revenue (56.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6660's Return on Equity is forecast to be high in 3 years time (23.1%)